The University of Chicago Header Logo

Connection

Yusuke Nakamura to Cancer Vaccines

This is a "connection" page, showing publications Yusuke Nakamura has written about Cancer Vaccines.
Connection Strength

5.674
  1. Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.
    View in: PubMed
    Score: 0.712
  2. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
    View in: PubMed
    Score: 0.692
  3. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunol Invest. 2021 Jul; 50(5):562-579.
    View in: PubMed
    Score: 0.643
  4. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012 Jul 09; 10:141.
    View in: PubMed
    Score: 0.369
  5. Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
    View in: PubMed
    Score: 0.350
  6. [Therapeutic cancer vaccines against gastro-intestinal cancer]. Nihon Shokakibyo Gakkai Zasshi. 2010 Aug; 107(8):1255-61.
    View in: PubMed
    Score: 0.323
  7. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Invest. 2022 Jul; 51(5):1498-1514.
    View in: PubMed
    Score: 0.174
  8. Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1371-1380.
    View in: PubMed
    Score: 0.140
  9. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
    View in: PubMed
    Score: 0.138
  10. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018 Mar; 109(3):542-549.
    View in: PubMed
    Score: 0.136
  11. miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. Cancer Sci. 2017 Nov; 108(11):2229-2238.
    View in: PubMed
    Score: 0.132
  12. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul; 108(7):1452-1457.
    View in: PubMed
    Score: 0.130
  13. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017 May; 50(5):1655-1662.
    View in: PubMed
    Score: 0.128
  14. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
    View in: PubMed
    Score: 0.127
  15. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
    View in: PubMed
    Score: 0.126
  16. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 01; 66(1):17-24.
    View in: PubMed
    Score: 0.124
  17. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
    View in: PubMed
    Score: 0.120
  18. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015 Jan 15; 21(2):312-21.
    View in: PubMed
    Score: 0.109
  19. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res. 2014 Aug; 34(8):4201-5.
    View in: PubMed
    Score: 0.106
  20. Guidance for peptide vaccines for the treatment of cancer. Cancer Sci. 2014 Jul; 105(7):924-31.
    View in: PubMed
    Score: 0.106
  21. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
    View in: PubMed
    Score: 0.104
  22. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
    View in: PubMed
    Score: 0.104
  23. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol. 2012 Jul; 42(7):591-600.
    View in: PubMed
    Score: 0.092
  24. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010 Feb; 101(2):433-9.
    View in: PubMed
    Score: 0.077
  25. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug; 100(8):1502-9.
    View in: PubMed
    Score: 0.074
  26. [Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2268-70.
    View in: PubMed
    Score: 0.071
  27. [A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
    View in: PubMed
    Score: 0.071
  28. Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Sci. 2008 Nov; 99(11):2315-26.
    View in: PubMed
    Score: 0.071
  29. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb; 56(2):43-53.
    View in: PubMed
    Score: 0.068
  30. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
    View in: PubMed
    Score: 0.023
  31. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6624-31.
    View in: PubMed
    Score: 0.017
  32. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.